SCHEMBL2827476

SCHEMBL2827476

Cc1onc(-c2ccccc2)c1C(=O)c1cc2cccc(OCc3ccccc3)c2o1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
MEN1 O00255 3/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TSHR P16473 4/20 0.45
POLB P06746 3/20 0.45
LMNA P02545 2/20 0.45
GAA P10253 2/20 0.45
ALDH1A1 P00352 2/20 0.45
HPGD P15428 1/20 0.45
HTT P42858 1/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
TDP1 Q9NUW8 1/20 0.43
ALOX15 P16050 1/20 0.43
MAPK1 P28482 1/20 0.43
ATM Q13315 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2829280 0.94 PIM1 (0.46) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2827876 0.94 POLB (0.49) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2829677 0.93 POLB (0.51) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2829178 0.92 ALDH1A1 (0.52) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2827742 0.91 GAA (0.50) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2828886 0.90 SMN1; SMN2 (0.51) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2825500 0.90 ALDH1A1 (0.48) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2827849 0.88 KMT2A (0.61) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2830575 0.87 NPC1 (0.40) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL2829309 0.86 PIM1 (0.48) KMT2AMEN1NPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1948648-B1 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURANE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-05-05 EP disclosed
EP-1948648-A2 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES F.HOFFMANN-LA ROCHE AG (CH) 2008-07-30 EP disclosed
US-7388025-B2 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives HOFFMAN-LA ROCHE INC. (US) 2008-06-17 US disclosed
WO-2007054444-A2 3-ARYL-ISOXAZOLE-4-CARBONYL-BENZOFURAN DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-05-18 WO disclosed
US-20070105922-A1 3-aryl-isoxazole-4-carbonyl-indole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105922-A1 3-aryl-isoxazole-4-carbonyl-indole derivatives GABRA5, GABRA4, GABRA3 KMT2A 2367/4885MEN1 4609/4885NPC1 1706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.